Volume 14, Number 10—October 2008
Research
Prophylaxis after Exposure to Coxiella burnetii
Claire E. Moodie
, Herbert A. Thompson, Martin I. Meltzer, and David L. Swerdlow
, Herbert A. Thompson, Martin I. Meltzer, and David L. Swerdlow
Table 4
Summary of threshold points by group, drug efficacy, and probability of an adverse event (best estimate/upper bound estimate)
| Population | Drug efficacy |
||||
|---|---|---|---|---|---|
| 96.50% | 40%* | 82% |
|||
| Primary analysis | Less virulent | More virulent | |||
| General population | |||||
| All cases of illness | 2.1/6.3 | NA | 2.5/7.4 | 3.88/11.65 | 1.98/5.94 |
| Severe illness | 0.08/0.24 | NA | 0.09/0.28 | 0.58/1.75 | 0.05/0.14 |
| Death |
0.00/1.8 |
NA |
0.00/2.1 |
0.00/28.49 |
0.00/0.36 |
| High-risk population | |||||
| All cases of illness | 2.1/6.3 | NA | 2.5/7.4 | 3.88/11.65 | 1.98/5.94 |
| Severe illness | 0.03/0.09 | NA | 0.03/0.10 | 0.147/0.44 | 0.021/0.06 |
| Death |
0.00/0.24 |
NA |
0.00/0.28 |
0.00/3.5 |
0.00/0.05 |
| Pregnant women | |||||
| All cases of illness | 4.7/13.3 | 11.4/32.2 | 5.6/15.7 | 9.99/28.2 | 4.16/11.7 |
| Severe illness | 0.002/0.006 | 0.005/0.014 | 0.002/0.007 | 0.0069/0.021 | 0.0016/0.0047 |
| Death | 0.001/0.004 | 0.003/0.010 | 0.002/0.005 | 0.0053/0.0156 | 0.0006/0.0019 |
*Doxycycline was not evaluated at 40% drug efficacy. NA, not available.
Page created: July 13, 2010
Page updated: July 13, 2010
Page reviewed: July 13, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.